BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: François B, Wittebole X, Ferrer R, Mira JP, Dugernier T, Gibot S, Derive M, Olivier A, Cuvier V, Witte S, Pickkers P, Vandenhende F, Garaud JJ, Sánchez M, Salcedo-Magguilli M, Laterre PF. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial. Intensive Care Med 2020;46:1425-37. [PMID: 32468087 DOI: 10.1007/s00134-020-06109-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Yu T, Tang Y, Zhang F, Zhang L. Roles of ginsenosides in sepsis. J Ginseng Res 2023;47:1-8. [PMID: 36644389 DOI: 10.1016/j.jgr.2022.05.004] [Reference Citation Analysis]
2 Zhang C, Kan X, Zhang B, Ni H, Shao J. The role of triggering receptor expressed on myeloid cells-1 (TREM-1) in central nervous system diseases. Mol Brain 2022;15:84. [PMID: 36273145 DOI: 10.1186/s13041-022-00969-w] [Reference Citation Analysis]
3 Schürmann M, Goon P, Sudhoff H. Review of potential medical treatments for middle ear cholesteatoma. Cell Commun Signal 2022;20:148. [PMID: 36123729 DOI: 10.1186/s12964-022-00953-w] [Reference Citation Analysis]
4 Muller M, Haghnejad V, Lopez A, Tiotiu A, Renaud S, Derive M, Bronowicki J. Triggering Receptors Expressed on Myeloid Cells 1 : Our New Partner in Human Oncology? Front Oncol 2022;12:927440. [DOI: 10.3389/fonc.2022.927440] [Reference Citation Analysis]
5 Siskind S, Brenner M, Wang P. TREM-1 Modulation Strategies for Sepsis. Front Immunol 2022;13:907387. [DOI: 10.3389/fimmu.2022.907387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Krychtiuk KA, Vrints C, Wojta J, Huber K, Speidl WS. Basic mechanisms in cardiogenic shock: part 2 – biomarkers and treatment options. European Heart Journal. Acute Cardiovascular Care 2022;11:366-374. [DOI: 10.1093/ehjacc/zuac022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ondigo BN, Hamilton RE, Magomere EO, Onkanga IO, Mwinzi PN, Odiere MR, Ganley-Leal L. Potential Utility of Systemic Plasma Biomarkers for Evaluation of Pediatric Schistosomiasis in Western Kenya. Front Immunol 2022;13:887213. [PMID: 35603171 DOI: 10.3389/fimmu.2022.887213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lu L, Liu X, Fu J, Liang J, Hou Y, Dou H. sTREM-1 promotes the phagocytic function of microglia to induce hippocampus damage via the PI3K-AKT signaling pathway. Sci Rep 2022;12:7047. [PMID: 35487953 DOI: 10.1038/s41598-022-10973-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhong Y, Xu Y, Xue S, Zhu L, Lu H, Wang C, Chen H, Sang W, Ma J. Nangibotide attenuates osteoarthritis by inhibiting osteoblast apoptosis and TGF-β activity in subchondral bone. Inflammopharmacology 2022. [PMID: 35391646 DOI: 10.1007/s10787-022-00984-2] [Reference Citation Analysis]
10 Vandestienne M, Joffre J, Lemarié J, Ait-Oufella H. [Role of TREM-1 in cardiovascular diseases]. Med Sci (Paris) 2022;38:32-7. [PMID: 35060884 DOI: 10.1051/medsci/2021242] [Reference Citation Analysis]
11 Jacobsen GE, Fernández I, Quintero MA, Santander AM, Pignac-kobinger J, Damas OM, Deshpande AR, Kerman DH, Ban Y, Gao Z, Silva TC, Wang L, Beecham AH, Mccauley JL, Burgueño JF, Abreu MT. Lamina Propria Phagocyte Profiling Reveals Targetable Signaling Pathways in Refractory Inflammatory Bowel Disease. Gastro Hep Advances 2022;1:380-392. [DOI: 10.1016/j.gastha.2022.01.005] [Reference Citation Analysis]
12 Lassus J, Tarvasmäki T, Tolppanen H. Biomarkers in cardiogenic shock. Advances in Clinical Chemistry 2022. [DOI: 10.1016/bs.acc.2022.03.002] [Reference Citation Analysis]
13 Ratain MJ, Tannock IF, Lichter AS. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? J Clin Oncol 2021;39:3423-6. [PMID: 34543056 DOI: 10.1200/JCO.21.01371] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
14 Vandestienne M, Zhang Y, Santos-Zas I, Al-Rifai R, Joffre J, Giraud A, Laurans L, Esposito B, Pinet F, Bruneval P, Raffort J, Lareyre F, Vilar J, Boufenzer A, Guyonnet L, Guerin C, Clauser E, Silvestre JS, Lang S, Soulat-Dufour L, Tedgui A, Mallat Z, Taleb S, Boissonnas A, Derive M, Chinetti G, Ait-Oufella H. TREM-1 orchestrates angiotensin II-induced monocyte trafficking and promotes experimental abdominal aortic aneurysm. J Clin Invest 2021;131:142468. [PMID: 33258804 DOI: 10.1172/JCI142468] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
15 de Nooijer AH, Grondman I, Lambden S, Kooistra EJ, Janssen NAF, Kox M, Pickkers P, Joosten LAB, van de Veerdonk FL, Derive M, Gibot S, Netea MG; RCI-COVID-19 study group. Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19. Biosci Rep 2021;41:BSR20210940. [PMID: 34195785 DOI: 10.1042/BSR20210940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Vignon P, Laterre PF, Daix T, François B. New Agents in Development for Sepsis: Any Reason for Hope? Drugs 2020;80:1751-61. [PMID: 32951149 DOI: 10.1007/s40265-020-01402-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
17 Jolly L, Carrasco K, Salcedo-Magguilli M, Garaud JJ, Lambden S, van der Poll T, Mebazaa A, Laterre PF, Gibot S, Boufenzer A, Derive M. sTREM-1 is a specific biomarker of TREM-1 pathway activation. Cell Mol Immunol 2021;18:2054-6. [PMID: 34282296 DOI: 10.1038/s41423-021-00733-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
18 Francois B, Lambden S, Gibot S, Derive M, Olivier A, Cuvier V, Witte S, Grouin JM, Garaud JJ, Salcedo-Magguilli M, Levy M, Laterre PF. Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial. BMJ Open 2021;11:e042921. [PMID: 34233965 DOI: 10.1136/bmjopen-2020-042921] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Cabri W, Cantelmi P, Corbisiero D, Fantoni T, Ferrazzano L, Martelli G, Mattellone A, Tolomelli A. Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives. Front Mol Biosci 2021;8:697586. [PMID: 34195230 DOI: 10.3389/fmolb.2021.697586] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
20 Nangibotid bei Patienten mit septischem Schock: eine Phase-IIa-Studie. Intensivmedizin up2date 2021;17:128-128. [DOI: 10.1055/a-1284-2829] [Reference Citation Analysis]
21 Leong K, Gaglani B, Khanna AK, McCurdy MT. Novel Diagnostics and Therapeutics in Sepsis. Biomedicines 2021;9:311. [PMID: 33803628 DOI: 10.3390/biomedicines9030311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Kimmoun A, Duarte K, Harjola VP, Tarvasmäki T, Levy B, Mebazaa A, Gibot S; CardShock Investigators and the GREAT network. Soluble triggering receptor expressed on myeloid cells-1 is a marker of organ injuries in cardiogenic shock: results from the CardShock Study. Clin Res Cardiol 2021. [PMID: 33677708 DOI: 10.1007/s00392-021-01823-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Matos AO, Dantas PHDS, Silva-Sales M, Sales-Campos H. TREM-1 isoforms in bacterial infections: to immune modulation and beyond. Crit Rev Microbiol 2021;47:290-306. [PMID: 33522328 DOI: 10.1080/1040841X.2021.1878106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Nangibotid bei Patienten mit septischem Schock: eine Phase-IIa-Studie. Anästhesiol Intensivmed Notfallmed Schmerzther 2021;56:6-7. [DOI: 10.1055/a-1305-1310] [Reference Citation Analysis]
25 Nangibotide bei Patienten mit septischem Schock: eine Phase-2a-Studie. Journal Club AINS 2020;09:229-231. [DOI: 10.1055/a-1252-9485] [Reference Citation Analysis]